Immunization MMWRs
May 2021
Hause AM, Gee J, Johnson T, Jazwa A, Marquez P, Miller E, et al. Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination — Five U.S. Mass Vaccination Sites, April 2021 MMWR. 2021;70(18);685-8.
Vaccine providers should be aware of anxiety-related events after vaccination and observe all COVID-19 vaccine recipients for any adverse reactions for at least 15 minutes after vaccine administration…-
Shay DK, Gee J, Su JR, Myers TR, Marquez P, Liu R, et al. Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021 MMWR. 2021;70(18);680-4.
This report summarizes adverse events among Janssen vaccine recipients, including non-CVST cases of thrombosis with thrombocytopenia syndrome (TTS), reported to the Vaccine Adverse Events Reporting System (VAERS), a passive surveillance system, and through v-safe, an active monitoring system… -
Tenforde MW, Olson SM, Self WH, Talbot HK, Lindsell CJ, Steingrub JS, et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021 MMWR. 2021;70(18);674-9.
SARS-CoV-2 vaccines significantly reduce the risk for COVID-19–associated hospitalization in older adults and, in turn, might lead to commensurate reductions in post-COVID conditions and deaths…
April 2021
-
MacNeil JR, Su JR, Broder KR, Guh AY, Gargano JW, Wallace M, et al. Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021 MMWR. 2021;70(17);651-6.
On April 23, the Advisory Committee on Immunization Practices concluded that the benefits of resuming Janssen COVID-19 vaccination among persons aged ≥18 years outweighed the risks and reaffirmed its interim recommendation under FDA’s Emergency Use Authorization, which includes a new warning for rare clotting events among women aged 18–49 years… -
Cavanaugh AM, Fortier S, Lewis P, Arora V, Johnson M, George K, et al. COVID-19 Outbreak Associated with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination Program — Kentucky, March 2021 MMWR. 2021;70(17);639-43.
Vaccination of SNF residents and HCP is essential to reduce the risk for symptomatic COVID-19, as is continued focus on infection prevention and control practices… -
Teran RA, Walblay KA, Shane EL, Xydis S, Gretsch S, Gagner A, et al. Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility Residents and Staff Members — Chicago, Illinois, December 2020–March 2021 MMWR. 2021;70(17);632-8.
SNFs should prioritize vaccination and follow recommended COVID-19 infection prevention and control practices, including following work restrictions, isolation, quarantine, testing of residents and staff members, and use of personal protective equipment… -
Salman O, Topf K, Chandler R, Conklin L. Progress in Immunization Safety Monitoring — Worldwide, 2010–2019 MMWR. 2021;70(15);547–51.
This report describes global progress toward meeting World Health Organization (WHO) indicators on minimal country capacity for vaccine safety surveillance and coordination of AEFI reporting between countries’ EPI and NRAs. In 2019, among 194 countries, 129 (66.5%) reported having an operational national AEFI causality review committee, compared with 94 (48.5%) in 2010…
March 2021
-
Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021 MMWR. 2021;70(13);495–500.
Authorized mRNA COVID-19 vaccines are effective for preventing SARS-CoV-2 infection in real-world conditions… -
Stern MF, Piasecki AM, Strick LB, Rajeshwar P, Tyagi E, Dolovich S, et al. Willingness to Receive a COVID-19 Vaccination Among Incarcerated or Detained Persons in Correctional and Detention Facilities — Four States, September–December 2020 MMWR. 2021;70(13);473–7.
This report underscores the urgent need for interventions that are culturally relevant and appropriate for various health literacy levels to increase vaccine confidence among incarcerated or detained persons… -
Rosenblum HG, Lewis RM, Gargano JW, Querec TD, Unger ER, Markowitz LE. Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine — United States, 2003–2018 MMWR. 2021;70(12);415–20.
This report adds to the robust data on the impact of the national HPV vaccination program, including herd effects… -
Hughes MM, Wang A, Grossman MK, Pun E, Whiteman A, Deng L, et al. County-Level COVID-19 Vaccination Coverage and Social Vulnerability — United States, December 14, 2020–March 1, 2021 MMWR. 2021;70(12);431–6.
Continued monitoring of vaccination coverage by social vulnerability metrics is critical for developing tailored, local vaccine administration and outreach efforts to reduce COVID-19 vaccination inequities… -
Britton A, Slifka KMJ, Edens C, Nanduri SA, Bart SM, Shang N, et al. Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks — Connecticut, December 2020–February 2021 MMWR. 2021;70(11);396–401.
Even with partial vaccination, Pfizer-BioNTech COVID-19 vaccine provides protection to SNF residents… -
Kriss JL, Reynolds LE, Wang A, Stokley S, Cole MM, Harris LQ, et al. COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 MMWR. 2021;70(11);389–95.
Identifying and addressing possible barriers to completing the COVID-19 vaccination series can help ensure equitable coverage across communities and optimal health benefits for recipients… -
Oliver SE, Gargano JW, Scobie H, Wallace M, Hadler SC, Leung J, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021 MMWR. 2021;70(9);329–32.
The Janssen COVID-19 vaccine has high efficacy against COVID-19–associated hospitalization and death…
February 2021
-
Rinott E, Youngster I, Lewis YE. Reduction in COVID-19 Patients Requiring Mechanical Ventilation Following Implementation of a National COVID-19 Vaccination Program — Israel, December 2020–February 2021 MMWR. 2021;70(9);326–8.
These findings provide preliminary evidence of the effectiveness of vaccines in preventing severe cases of COVID-19 at the national level in Israel… -
Gee J, Marquez P, Su J, Calvert GM, Liu R, Myers T, Nair N, et al. First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021 MMWR. 2021;70(8);283–8.
Monitoring, conducted as part of the U.S. vaccination program, indicates reassuring safety profiles for COVID-19 vaccines… -
Batdorf SJ, Hofmeister MG, Surtees TC, Thomasson ED, McBee SM, Pauly NJ. Estimated Medicaid Costs Associated with Hepatitis A During an Outbreak — West Virginia, 2018–2019 MMWR. 2021;70(8);269–72.
the results from this study highlight the potential financial cost jurisdictions might incur when ACIP recommendations for hepatitis A vaccination, especially among persons who use illicit drugs, are not followed… -
Hong K, Zhou F, Tsai Y, Jatlaoui TC, Acosta AM, Dooling KL, et al. Decline in Receipt of Vaccines by Medicare Beneficiaries During the COVID-19 Pandemic — United States, 2020 MMWR. 2021;70(7);245–9.
Vaccination providers should emphasize the importance of routine adult vaccination to their patients and ensure the safe provision of vaccines to protect older adults from vaccine-preventable diseases during the ongoing COVID-19 pandemic… -
Nguyen KH, Srivastav A, Razzaghi H, Williams W, Lindley MC, Jorgensen C, et al. COVID-19 Vaccination Intent, Perceptions, and Reasons for Not Vaccinating Among Groups Prioritized for Early Vaccination — United States, September and December 2020 MMWR. 2021;70(6);217–22.
Ensuring high and equitable vaccination coverage among all populations, including by addressing reasons for not intending to receive vaccination, is critical to prevent the spread of COVID-19 and bring an end to the pandemic… -
Freedman MS, Ault K, Bernstein H. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2021 MMWR. 2021;70(6);193–6.
The 2021 adult immunization schedule summarizes ACIP recommendations, including several changes from the 2020 immunization schedule on the cover page, two tables, and accompanying notes found on the CDC immunization schedule website… -
Wodi AP, Ault K, Hunter P, McNally V, Szilagyi PG, Bernstein H. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2021 MMWR. 2021;70(6);189–92.
The 2021 child and adolescent immunization schedule summarizes ACIP recommendations, including several changes from the 2020 immunization schedule on the cover page, two tables, and notes found on the CDC immunization schedule website… -
Gharpure R, Guo A, Bishnoi CK, Patel U, Gifford D, Tippins A, et al. Early COVID-19 First-Dose Vaccination Coverage Among Residents and Staff Members of Skilled Nursing Facilities Participating in the Pharmacy Partnership for Long-Term Care Program — United States, December 2020–January 2021 MMWR. 2021;70(5);178–82.
Barriers to SNF staff member vaccination need to be overcome with continued development and implementation of focused communication and outreach strategies to improve vaccination coverage… -
Painter EM, Ussery EN, Patel A, PharmD, Hughes MM, Zell ER, MStat, Moulia DL, et al. Demographic Characteristics of Persons Vaccinated During the First Month of the COVID-19 Vaccination Program — United States, December 14, 2020–January 14, 2021 MMWR. 2021;70(5);174–7.
As the vaccination program expands, it is critical to ensure efficient and equitable administration to persons in each successive vaccine priority category, especially those at highest risk for infection and severe health outcomes…
January 2021
-
CDC COVID-19 Response Team; Food and Drug Administration. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021 MMWR. 2021;70(4);125–9.
This report summarizes the clinical and epidemiologic characteristics of case reports of allergic reactions, including anaphylaxis and nonanaphylaxis allergic reactions, after receipt of the first dose of Moderna COVID-19 vaccine during December 21, 2020–January 10, 2021, in the United States. CDC has issued updated interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States and interim considerations for preparing for the potential management of anaphylaxis… -
Seither R, McGill MT, Kriss JL, Mellerson JL, Loretan C, Driver K, et al. Vaccination Coverage with Selected Vaccines and Exemption Rates Among Children in Kindergarten — United States, 2019–20 School Year MMWR. 2021;70(3);75–82.
This report provides data on overall national and median vaccination coverage for the state-required number of doses of DTaP, MMR, and varicella vaccine… -
Choi MJ, Cossaboom CM, Whitesell AN, Dyal JW, Joyce A, Morgan RL, et al. Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020 MMWR. 2021;70(RR-1);1–12.
This report summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the rVSVΔG-ZEBOV-GP Ebola vaccine (Ervebo) in the United States… -
CDC COVID-19 Response Team; Food and Drug Administration. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020 MMWR. 2021;70(2);46–51.
This report summarizes the clinical and epidemiologic characteristics of case reports of allergic reactions, including anaphylaxis and nonanaphylaxis allergic reactions, after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine during December 14–23, 2020, in the United States… -
Dooling K, Marin M, Wallace M, McClung N, Chamberland M, Lee GM, et al. The Advisory Committee on Immunization Practices’ Updated Interim Recommendation for Allocation of COVID-19 Vaccine — United States, December 2020 MMWR. 2021;69(5152);1657–60.
In Phase 1b, COVID-19 vaccine should be offered to persons aged ≥75 years and non–health care frontline essential workers, and in Phase 1c, to persons aged 65–74 years, persons aged 16–64 years with high-risk medical conditions, and essential workers not included in Phase 1b… -
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020 MMWR. 2021;69(51);1653–6.
On December 19, 2020, after a transparent, evidence-based review of available data, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the Moderna COVID-19 vaccine in persons aged ≥18 years for the prevention of COVID-19…
- Archived MMWRs Related to Immunization News: 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011
- Influenza-related MMWRs
- Surveillance-related MMWRs
- Immunization Works!
- More news resources